Up 70%, Peregrine's Clinical Lemon Becomes Lemonade

Since the company's clinical data mix-up in a non-small-cell lung cancer study of bavituximab, Peregrine investors have been anxiously waiting to see what, if any, life might remain for the drug in this potentially lucrative indication. Today, the company released interim findings from its investigation into the mishap, and, as one might expect to see from a company with its back against the wall, the findings were considered positive. However, as Brenton Flynn discusses in the following video, investor should approach this with a "once bitten, twice shy" mentality.

If you're an investor looking for huge long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.